Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
T. Wakatsuki
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
Observed institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
ORCID:
0000-0002-1463-3859
Observed ORCID:
0000-0002-1463-3859
OpenAlex ID:
A5019069276
Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice
2025
·
K. Shimozaki
, A. Ooki
, et al.
·
ESMO Gastrointestinal Oncology
·
22
PDF
Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution?
2025
·
K. Shimozaki
, A. Ooki
, et al.
·
ESMO Gastrointestinal Oncology
·
9
PDF
The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy
2025
·
S. Udagawa
, A. Ooki
, et al.
·
ESMO Gastrointestinal Oncology
·
6
PDF
1244P Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)
2022
·
N. Boku
, C. Kudo-Saito
, et al.
·
Annals of Oncology
·
3
PDF
Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy
2026
·
A. Ooki
, K. Nakano
, et al.
·
ESMO Gastrointestinal Oncology
·
1
PDF
Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination
2025
·
Y. Suzuki
, K. Shimozaki
, et al.
·
ESMO Gastrointestinal Oncology
·
1
PDF
Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer
2026
·
A. Ooki
, K. Shimozaki
, et al.
·
ESMO Gastrointestinal Oncology
PDF
109P KRAS G12C versus non-G12C mutated metastatic colorectal cancer: Real-world later-line clinical outcomes
2026
·
K. Yoshikawa
, H. Osumi
, et al.
·
Annals of Oncology
92P Circulating tumor DNA RAS mutant allele frequency as a predictor of efficacy of anti-EGFR monoclonal antibody rechallenge in patients with metastatic colorectal cancer
2026
·
E. Toyokawa
, H. Osumi
, et al.
·
Annals of Oncology
93P Clinical utility of tissue-based negative hyper selection for optimizing targeted therapy in metastatic colorectal cancer
2026
·
K. Suzuki
, H. Osumi
, et al.
·
Annals of Oncology
PDF
604P Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: Follow-up data from real-world experience
2026
·
K. Shimozaki
, O. Akira
, et al.
·
Annals of Oncology
BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer
2026
·
T. Wakatsuki
, T. Mashima
, et al.
·
ESMO Gastrointestinal Oncology
825P Successful steroid-sparing management of G-CSF-associated large-vessel vasculitis
2025
·
Y. Morita
, K. Takeda
, et al.
·
Annals of Oncology
770P Impact of ctDNA testing on decision-making for adjuvant chemotherapy in colorectal cancer: A prospective multicenter study
2025
·
S. Fukuoka
, H. Osumi
, et al.
·
Annals of Oncology
2816P Higher initial doses of corticosteroid shorten the total duration of corticosteroid in the management of immune-related adverse events (irAEs) in gastrointestinal tumors
2025
·
E. Tange
, K. Takeda
, et al.
·
Annals of Oncology
489P Efficacy of immune checkpoint inhibitors in patients with dMMR/MSI-H advanced gastric cancer and metastatic colorectal cancer in clinical practice
2025
·
S. Udagawa
, H. Osumi
, et al.
·
Annals of Oncology
PDF
1465P Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
2024
·
T. Wakatsuki
, T. Mashima
, et al.
·
Annals of Oncology
PDF
567P Interim endoscopic restaging after induction chemotherapy to predict complete response and survival after total neoadjuvant therapy in low rectal cancer: Ad-hoc analysis of the IMPACT trial
2024
·
E. Shinozaki
, H. Osumi
, et al.
·
Annals of Oncology
1561P APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab)
2023
·
T. Wakatsuki
, D. Takahari
, et al.
·
Annals of Oncology
PDF
448TiP A multicenter single arm phase II trial evaluating the safety and the efficacy of panitumumab and irinotecan for patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial)
2022
·
H. Osumi
, N. Ishizuka
, et al.
·
Annals of Oncology
1391P Clinical progress in inoperable or recurrent advanced gastric cancer treatment from 1,004 single institute experiences between 2007 and 2018
2021
·
I. Nakayama
, D. Takahari
, et al.
·
Annals of Oncology
1426P The utility of the prognostic index for practicing the continuum of care in advanced gastric cancer: The suitability assessment and modification of the JCOG prognostic index in real-world data
2021
·
K. Shimozaki
, I. Nakayama
, et al.
·
Annals of Oncology
Comparison of HER2 related molecular expression and its significance for clinical outcomes between the primary and paired liver metastasis in advanced gastric cancer
2017
·
H. Osumi
, E. Shinozaki
, et al.
·
Annals of Oncology
P-262 The impact of variations in KRAS codon 12 and 13 point mutation on the efficacy of cytotoxic chemotherapy for metastatic colorectal cancer (CRC)
2015
·
I. Nakayama
, E. Shinozaki
, et al.
·
Annals of Oncology
PDF
Chemosensitivity testing to predict chemosensitivity for gemcitabine, using the biopsy specimens obtained by EUS-FNA from unresectable pancreatic cancer.
2010
·
T. Wakatsuki
, A. Irisawa
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
25
Citation count:
42
H-index:
3
I10-index:
1
Year
Topic
Type